Longitudinal gene expression profiling of self-collected blood samples in COVID-19+ and healthy participants
Ontology highlight
ABSTRACT: Longitudinal cohort: 773 host response genes were profiled in previously vaccinated (n=16) and unvaccinated (n=14) COVID-19+ participants along with 5 healthy uninfected controls across a 2-week observational window Single timepoint cohort: 773 host response genes were profiled in 6 healthy uninfected participants
Project description:We performed single-nucleus RNA-seq on subcutaneous adipose tissue biopsies of 68 participants from the Roux-en-Y versus one-anastomosis gastric bypass (RYSA) cohort.
Project description:DSP RNA profiling using the whole transcriptome atlas kit was performed on a cohort of placentae from participants who had contracted SARS-CoV-2 in the third trimester compared to uninfected controls.
Project description:Transcriptomic profiling was conducted on whole blood collected from study participants (NCT04480957). A total of 106 healthy participants were randomized into single and two-injection cohorts. Gene transcript levels were determined at baseline (pre-dose 1), day 2, 3, and 8 for all vaccinees. In addition, gene expression was profiled at day 29 (pre-dose 2), 30 and 36 among vaccinees in the two-injection cohort. Whole blood was collected in Tempus Blood RNA tubes, and RNA was extracted from whole blood using the Tempus Spin RNA Isolation Kit.
Project description:We performed single-nucleus RNA-seq using 10X on 84 randomly sampled participants from the METabolic Syndrome In Men (METSIM) cohort. The purpose of the study was to characterize cell type composition changes associated with metabolic diseases such as obesity and type 2 diabetes.
Project description:EPIC array data were generated from 2 MDD case control cohorts. EWAS was performed in each cohort, followed by meta-analysis between the 2 cohort. Cohort 1: A total of 191 blood samples from 112 patients with MDD was collected up till the interim analysis (wave 1 samples) from an observational clinical study OBSERVEMDD0001 (ClinicalTrials.gov Identifier: NCT02489305) compared to 32 healthy controls; Cohort 2: The MDD cases (N = 359) were drawn from the Molecular Biomarkers of Antidepressant Response study compared to 68 healthy controls.
Project description:In this study, investigators recruited the largest reported cohort of tolerant kidney transplant recipients who maintained their graft after ceasing to take their immunosuppression drug, and compared this cohort to subjects with stable allograft function while on immunosuppression and healthy non transplated, controls. Using gene expression studies, they identified genetic markers that are strong candidates for predicting kidney transplant candidates who may benefit from minimization or withdrawl of immunosuppression. Microarrays were used to detect expressed gene profiles of whole-blood total RNA from subjects in the tolerant, standard immunotherapy and healthy control participants Total of 19 Tolerant (TOL) participants, 27 Standard Immunotherapy (SI) participants, and 12 Healthy Controls (HC)
Project description:European-American individuals of the GENOA cohort participating in the “Genetics of Microangiopathic Brain Injury” substudy, which investigates the genetic basis of alteration in brain structure detectable by magnetic resonance imaging. This analysis investigated the association of gene expression with age (at the time of cell transformation). Participants in this study are drawn from the GENOA study, a population-based study from Rochester, MN